Anidulafungin

drugbox
IUPAC_name =

---

width = 300px
CAS_number = 166663-25-8
ATC_prefix = J02
ATC_suffix = AX06
ATC_supplemental =
PubChem = 166548
DrugBank = APRD01301
C=58 | H=73 | N=7 | O=17
molecular_weight = 1140.24 g/mol
bioavailability =
protein_bound = 84%
metabolism =
elimination_half-life = 40-50 hours
pregnancy_category =
legal_status =
routes_of_administration =

Anidulafungin or Eraxis (Ecalta in Europe) is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006 [http://www.fda.gov/bbs/topics/news/2006/NEW01321.html] ; it was previously known as LY303366. There is preliminary evidence that it has a similar safety profile to caspofungin. It has proven efficacy against oesophageal candidiasis, but its main utility will probably be in invasive "Candida" infection; it will probably also have application in treating invasive Aspergillus infection. It is a member of the class of anti-fungal drugs known as the echinocandins: its mechanism of action is by inhibition of (1→3)β-D-glucan synthase, which is an important component of the fungal cell wall.

Pharmacokinetics

Anidulafungin significantly differs from other antifungals in that it undergoes chemical degradation to inactive forms at body pH and temperature. Because it does not rely on enzymatic degradation or hepatic or renal excretion, the drug is safe to use in patients with any degree of hepatic or renal impairment. [cite web|title=RxList|url=http://www.rxlist.com/cgi/generic/eraxis_cp.htm|accessdate=2008-01-06]

References

*
*
*